Maris Pamela, Campana Antonella, Barone Ines, Giordano Cinzia, Morelli Catia, Malivindi Rocco, Sisci Diego, Aquila Saveria, Rago Vittoria, Bonofiglio Daniela, Catalano Stefania, Lanzino Marilena, Andò Sebastiano
Department of Pharmacy, Health and Nutritional Sciences (P.M., A.C., I.B., C.M., R.M., D.S., S.Aq., V.R., D.B., S.C., M.L., S.An.) and Centro Sanitario (C.G., D.S., S.Aq., D.B., S.C., M.L., S.An.), University of Calabria, 87036 Arcavacata di Rende (Cosenza), Italy.
Endocrinology. 2015 Apr;156(4):1251-62. doi: 10.1210/en.2014-1654. Epub 2015 Jan 20.
Leydig cell tumors (LCTs) of the testis are steroid-secreting tumors associated with various steroid biosynthetic abnormalities and endocrine dysfunctions. Despite their overall rarity, LCTs are still of substantial interest owing to the paucity of information regarding their exact nature and malignant potential. In the present study, we disclose the ability of androgens to inhibit Leydig tumor cell proliferation by opposing to self-sufficient in situ estrogen production. In rat Leydig tumor cells, R2C, androgen treatment significantly decreases the expression and the enzymatic activity of cytocrome P450 aromatase, responsible for the local conversion of androgens into estrogens. This inhibitory effect relies on androgen receptor (AR) activation and involves negative regulation of the CYP19 gene transcriptional activity through the nuclear orphan receptor DAX-1 (dosage-sensitive sex reversal, adrenal hypoplasia critical region, on chromosome X, gene 1). Ligand-activated AR up-regulates the expression of DAX-1 and promotes its increased recruitment within the steroidogenic factor-1 site-containing region of the aromatase proximal promoter II in association with the nuclear receptor corepressor. The biological relevance in LCTs of the newly highlighted functional interplay between AR, DAX-1, and aromatase is underlined by our in vivo observations, revealing a marked down-regulation of AR and DAX-1 expression and a strong increase in aromatase levels in testes tissues from old Fischer rats with spontaneously developed Leydig cell neoplasia, compared with normal testes tissues from younger animals. In elucidating a mechanism by which androgens modulate the growth of Leydig tumor cells, our finding support the hypothesis that maintaining the adequate balance between androgen and estrogens may represent the key for blocking estrogen-secreting Leydigioma development, opening new prospects for therapeutic intervention.
睾丸间质细胞瘤(LCTs)是与各种类固醇生物合成异常和内分泌功能障碍相关的类固醇分泌肿瘤。尽管总体罕见,但由于关于其确切性质和恶性潜能的信息匮乏,LCTs仍备受关注。在本研究中,我们揭示了雄激素通过对抗原位雌激素的自分泌来抑制间质肿瘤细胞增殖的能力。在大鼠间质肿瘤细胞R2C中,雄激素处理显著降低了细胞色素P450芳香化酶的表达和酶活性,该酶负责雄激素在局部转化为雌激素。这种抑制作用依赖于雄激素受体(AR)的激活,并涉及通过核孤儿受体DAX-1(剂量敏感性性别反转、肾上腺发育不全关键区域,位于X染色体,基因1)对CYP19基因转录活性的负调控。配体激活的AR上调DAX-1的表达,并促进其与核受体共抑制因子结合,在芳香化酶近端启动子II含类固醇生成因子-1位点的区域内募集增加。我们的体内观察结果强调了AR、DAX-1和芳香化酶之间新发现的功能相互作用在LCTs中的生物学相关性,结果显示,与年轻动物的正常睾丸组织相比,自发发生间质细胞瘤的老年Fischer大鼠睾丸组织中AR和DAX-1表达显著下调,芳香化酶水平显著升高。在阐明雄激素调节间质肿瘤细胞生长的机制时,我们的发现支持了这样一种假说,即维持雄激素和雌激素之间的适当平衡可能是阻止分泌雌激素的间质细胞瘤发展的关键,为治疗干预开辟了新的前景。